| Status | Study |
| Recruiting |
Study Name: Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) Condition: Cutaneous T-Cell Lymphoma Date: 2015-10-29 Interventions: Biological: IPH4102 |
| Recruiting |
Study Name: Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) Condition: Cutaneous T Cell Lymphoma Date: 2015-09-06 Interventions: Drug: dimethylfumarate dose escalation from 30 mg/d to 720 mg/d over 9 weeks following a preset design i |
| Recruiting |
Study Name: Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Condition: Lymphoma, T-Cell, Cutaneous Mycosis Fungoides Date: 2014-12-12 Interventions: Drug: Methotrexate Methotrexat |
| Recruiting |
Study Name: Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Condition: Cutaneous T Cell Lymphoma Date: 2014-07-10 Interventions: Drug: Micro needle array-Doxorubicin (MNA-D) MNA-D patches will be applied to 3-4 CTCL skin patches or p |
| Recruiting |
Study Name: Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma Condition: Cutaneous T-cell Lymphoma Date: 2014-02-11 Interventions: Drug: Romidepsin Other Names: |
| Withdrawn |
Study Name: Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) Condition: Cutaneous T-cell Lymphoma (CTCL) Date: 2013-04-24 Interventions: Drug: Sirolimus 0.1% Ointment Sirolimus 0.1% ointment will be applied topically to all affected areas of |
| Recruiting |
Study Name: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Condition: Persistent or Recurrent Cutaneous T-Cell Lymphoma Date: 2013-03-28 Interventions: Drug: E7777 administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive |
| Active, not recruiting |
Study Name: Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) Condition: Cutaneous T Cell Lymphoma Date: 2012-07-15 Interventions: Drug: Topical resiquimod 0.06% |
| Terminated |
Study Name: Everolimus in Treating Cutaneous T-cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2012-04-02 Interventions: Drug: Everolimus The study drug everolimus will be self-ad |
| Completed |
Study Name: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Condition: Lymphoma, T-Cell, Cutaneous Date: 2011-11-29 Interventions: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |